Ginebra, Suiza - 27 de junio de 2003
Sources and prices of HIV/AIDS medicines and diagnostic tests û New EditionUpdated version to assist in efforts towards better access to reliable information
The report gives purchasers of AIDS medicines and diagnostics a range of choices related to suppliers and affordability. The medicines included were selected on the basis of WHO standard treatment guidelines. The list is not exhaustive but covers the most commonly used HIV/AIDS medicines, with paediatric forms included wherever possible.
Improving access to medicines for people living with HIV/AIDS is a challenge for all countries but especially for developing ones. By the end of 2002, UNAIDS estimated that 42 million people in the world were living with HIV/AIDS and that over 95% of these were in poor nations. Last year, 3.1 million people died of the disease, many of them because they had had no access to treatment.
While high prices constitute one of the main barriers to accessing treatment, a few recent initiatives have brought the price of certain medicines down. However, even where affordable alternatives exist, many decisionûmakers do not have the information they need to identify those manufacturers that can supply the medicines needed. Without such information, there is a risk that lowûincome countries pay more than necessary &*150; and sometimes more than industrialized countries &*150; to obtain essential medicines. The report helps fill that gap.
This report is the fourth in a series of annual publications of sources and prices surveys commenced in 1999 by United Nations Children&*146;s Fund (UNICEF), UNAIDS, the World Health Organization (WHO) and Médecins Sans Frontières (MSF). The present edition is the result of a survey carried out from December 2002 through February 2003, of 388 manufacturers in 50 countries.
The report includes antiretroviral (ARV) medicines, medicines used to treat a range of opportunistic infections, medicines for use in palliative care, medicines for the treatment of HIVûrelated cancers and for the management of opioid dependence. It also provides information on a range of test kits for the diagnosis and monitoring of HIV/AIDS.
A new section has been added on the registration status of products in the survey. This information will be useful for people in countries who are in the process of granting market authorization to HIV/AIDS related products.
Finally, the latest edition of an MSF document, Untangling the Web of Price Reductions: a pricing guide for the purchase of ARVs for developing countries has been included as an annex to provide a comprehensive overview of the prices of ARV medicines offered by researchûbased pharmaceutical companies and some generics manufacturers in lowû and middleûincome countries.